CCCC C4 Therapeutics, Inc.
Company Analysis
Latest News
C4 Therapeutics Shareholders Approve Amendment to 2020 Stock Incentive Plan
C4 Therapeutics announced the results of its Annual Meeting of Stockholders held on June 24, 2026, where shareholders approved an amendment to the company's...
🟢 CCCC is trading 8.1% up today, extending its recent uptrend despite no clear catalyst
CCCC is trading 8.1% up today at $4.46, extending its strong recent uptrend despite a lack of fresh company-specific news. • No new press releases, FDA...
🟢 C4 Therapeutics Inc is trading 5.2% up today as company presents positive Phase 1 cemsidomide data
C4 Therapeutics Inc is trading 5.2% up today at $4.04 following the presentation of positive Phase 1 data for its cemsidomide drug at the European Hematology...
🔴 C4 Therapeutics Inc is trading 5.2% down today amid a lack of clear catalysts
C4 Therapeutics Inc is trading 5.2% down at $3.62 today amid a lack of fresh, company-specific news or filings pointing to a clear catalyst for the move. •...
🟢 C4 Therapeutics Inc is trading 5.1% up today on positive Phase 1 multiple myeloma data
C4 Therapeutics Inc is trading 5.1% up at $4.10 in after-hours trading following the presentation of positive Phase 1 data for its CELMoD degrader,...
🟢 C4 Therapeutics Inc is trading 5.7% up today on positive EHA data for cemsidomide in multiple myeloma
C4 Therapeutics Inc is trading 5.7% up at $4.09 following the presentation of positive Phase 1 data for cemsidomide at the EHA Congress. • The trial for...
Reports 53% Overall Response Rate in Phase 1 Cemsidomide Trial for Multiple Myeloma
C4 Therapeutics presented further analysis from its fully enrolled Phase 1 trial of cemsidomide for relapsed/refractory multiple myeloma (RRMM) at the European...
🟢 C4 Therapeutics Inc is trading 5.2% up today as buying interest grows ahead of Goldman Sachs healthcare conference
C4 Therapeutics Inc is trading 5.2% higher at $3.77 as buying interest picks up ahead of management's participation in the Goldman Sachs 47th Annual Global...
🟢 C4 Therapeutics Inc up 5.2% amid Goldman Sachs Healthcare Conference participation
C4 Therapeutics Inc is trading at $3.77 (5.2%) in pre-market amid management's participation in a major investor conference. • The company is scheduled to...
🟢 C4 Therapeutics Inc is trading 7.2% up today on a technical recovery after a recent pullback
C4 Therapeutics Inc is trading at $3.85 (+7.2%), rebounding after a sharp multi-session pullback following its late-May/early-June rally. • The stock has...
🔴 C4 Therapeutics Inc is trading 6.3% down today on profit-taking and high volatility after recent rally
C4 Therapeutics Inc is trading at $3.61 (down 6.3%) as the stock extends a multi-session pullback following a strong rally in late May and early June. •...
🔴 C4 Therapeutics Inc is trading 5.3% down today on profit-taking and broader risk-off sentiment
C4 Therapeutics Inc is trading at $3.95 (5.3% down) as the stock pulls back following a sharp multi-day rally and recent analyst upgrades that had previously...
C4 Therapeutics Gains Analyst Upgrades on Cemsidomide Progress
C4 Therapeutics received upgraded analyst ratings in early June 2026. Zacks issued a 'Buy' rating on June 1. These upgrades reflect an upward trend in earnings...
🟢 C4 Therapeutics Inc is trading 6.57% up
CCCC is trading at $4.22, up 6.57%.
🟢 C4 Therapeutics Inc is trading 8.08% up
CCCC is trading at $4.28, up 8.08%.
🟢 C4 Therapeutics Inc is trading 8.84% up
CCCC is trading at $4.31, up 8.84%.
🟢 C4 Therapeutics Inc is trading 11.74% up
CCCC is trading at $4.42, up 11.74%.
C4 Therapeutics Price Target Increased to $12.00 by Evercore ISI
On June 1, 2026, Evercore ISI Group reaffirmed its positive outlook on C4 Therapeutics (NASDAQ: CCCC). The investment bank maintained an "Outperform" rating on...